ATHIRA PHARMA INC (ATHA)
US04746L1044 - Common Stock
Taking everything into account, ATHA scores 2 out of 10 in our fundamental rating. ATHA was compared to 193 industry peers in the Pharmaceuticals industry. While ATHA seems to be doing ok healthwise, there are quite some concerns on its profitability. ATHA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ATHA has reported negative net income.
ATHA had a negative operating cash flow in the past year.
ATHA had negative earnings in each of the past 5 years.
ATHA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ATHA's Return On Assets of -126.64% is on the low side compared to the rest of the industry. ATHA is outperformed by 83.16% of its industry peers.
With a Return On Equity value of -189.68%, ATHA is not doing good in the industry: 70.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.64% | ||
| ROE | -189.68% | ||
| ROIC | N/A |
ROA(3y)-42.33%
ROA(5y)-73.74%
ROE(3y)-49.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ATHA has been increased compared to 1 year ago.
Compared to 5 years ago, ATHA has more shares outstanding
There is no outstanding debt for ATHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -9.60, we must say that ATHA is in the distress zone and has some risk of bankruptcy.
ATHA's Altman-Z score of -9.60 is on the low side compared to the rest of the industry. ATHA is outperformed by 74.74% of its industry peers.
ATHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.6 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ATHA has a Current Ratio of 2.95. This indicates that ATHA is financially healthy and has no problem in meeting its short term obligations.
ATHA has a Current ratio of 2.95. This is comparable to the rest of the industry: ATHA outperforms 49.47% of its industry peers.
ATHA has a Quick Ratio of 2.95. This indicates that ATHA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.95, ATHA is in line with its industry, outperforming 53.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.95 |
3. Growth
3.1 Past
ATHA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.06%.
EPS 1Y (TTM)2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ATHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.29%
EPS Next 2Y16.64%
EPS Next 3Y20.11%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ATHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ATHA's earnings are expected to grow with 20.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.64%
EPS Next 3Y20.11%
5. Dividend
5.1 Amount
ATHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATHIRA PHARMA INC
NASDAQ:ATHA (12/26/2024, 8:00:01 PM)
After market: 0.5281 -0.01 (-1.93%)0.5385
0 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners49.3%
Inst Owner Change-28.92%
Ins Owners1.77%
Ins Owner Change3.23%
Market Cap20.70M
Analysts48.89
Price Target0.56 (3.99%)
Short Float %5.7%
Short Ratio0.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.37%
Min EPS beat(2)-4.12%
Max EPS beat(2)6.86%
EPS beat(4)3
Avg EPS beat(4)11.16%
Min EPS beat(4)-4.12%
Max EPS beat(4)27.47%
EPS beat(8)5
Avg EPS beat(8)6.25%
EPS beat(12)9
Avg EPS beat(12)7.21%
EPS beat(16)12
Avg EPS beat(16)9.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10%
PT rev (3m)-92.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.24%
EPS NY rev (1m)-1.33%
EPS NY rev (3m)3.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.36 | ||
| P/tB | 0.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.85
EYN/A
EPS(NY)-1.98
Fwd EYN/A
FCF(TTM)-2.54
FCFYN/A
OCF(TTM)-2.54
OCFYN/A
SpS0
BVpS1.5
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -126.64% | ||
| ROE | -189.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.33%
ROA(5y)-73.74%
ROE(3y)-49.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.79% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.95 | ||
| Altman-Z | -9.6 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)164.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y16.29%
EPS Next 2Y16.64%
EPS Next 3Y20.11%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.31%
EBIT Next 3Y13.38%
EBIT Next 5YN/A
FCF growth 1Y-26.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.97%
OCF growth 3YN/A
OCF growth 5YN/A